Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...

MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...

Navan will be the first large company to debut without a fully functioning Securities and Exchange Commission.

MapLight has become the second Massachusetts-linked biotech to go public this year. The company sold 14.75 million shares at ...

MapLight Therapeutics Inc. will raise $258.9 million in an initial public offering and private placement, becoming the first ...

Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at $17.00 per share, which works out to an IPO of around $251m. The biotech ...

Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical ...

Jyong Biotech Ltd., a Taiwan-based biotechnology company, recently completed its IPO on Nasdaq and participated in the BIO 2025 International Convention in Boston, where it showcased its flagship ...

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative ...

Based on the last month's worth of biotech initial public offerings, the planned IPO of Proteon this week could be a struggle. Proteon Therapeutics of Waltham is tentatively set to go public tomorrow ...